publication venue for
- Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2– advanced breast cancer in Chinese women. 88:131-141. 2021
- Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues. 72:127-138. 2013
- Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours. 71:543-549. 2013
- Primary tumor and patient characteristics in breast cancer as predictors of adjuvant therapy regimen: a regression model. 68:661-668. 2011
- A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer. 67:927-933. 2011
- A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. 66:1079-1085. 2010
- Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter. 59:621-629. 2007
- A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy. 57:412-426. 2006
- Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy. 57:427-435. 2006
- Human cells deficient in transcription-coupled repair show prolonged activation of the Jun N-terminal kinase and increased sensitivity following cisplatin treatment. 56:189-198. 2005
- Inhibition by doxycycline of angiogenesis in the chicken chorioallantoic membrane (CAM). 56:1-9. 2005
- Pancratistatin causes early activation of caspase-3 and the flipping of phosphatidyl serine followed by rapid apoptosis specifically in human lymphoma cells. 56:29-38. 2005
- Carboplatin hypersensitivity presenting as coronary vasospasm - a case report. 50:429-431. 2002
- Arterial occlusion in patients with peripheral vascular disease treated with platinum-based regimens for lung cancer. 40:19-22. 1997
- Nucleotide excision repair in the human ovarian carcinoma cell line (2008) and its cisplatin-resistant variant (C13*). 38:245-253. 1996
- Taxol encapsulation in poly(epsilon-caprolactone) microspheres. 36:279-282. 1995
- Lack of evidence for a high-affinity sarcosinamide carrier or a catecholamine carrier in Calu-1 lung-cancer cells, HT-29 colon-cancer cells, and DHF fibroblasts. 31:146-150. 1992
- Evidence for lack of mitochondrial DNA repair followingcis-dichlorodiammineplatinum treatment. 26:97-100. 1990
- Effect of whole-body hyperthermia on hepatic cytochrome P450. 25:342-344. 1990
- Interaction of VP16-213 with the DNA repair antagonist chloroquine. 7:123-126. 1982
- Podophyllotoxin derivative VP 16-213. 3:71-80. 1979